Biotech
-
Flagship outlines plans to raise $3B for new fund
The biotech company creator’s last fund, which closed in 2021, brought in $3.4 billion for investing in new drug startups.
Read More » -
FDA investigating cancer risk linked to CAR-T cell therapy
The agency said the benefit of approved treatments like Gilead’s Yescarta still outweighs any such risk, but the alert could…
Read More » -
Flagship-backed microbiome biotech Evelo to shut down
The company said it had not found “a viable alternative” to closing down in the months since it hit a…
Read More » -
Freeline, after cuts, agrees to take-private deal with Syncona
The planned acquisition adds to a string of bargain buyouts and reverse mergers in the gene therapy field.
Read More » -
Merck to buy private biotech Caraway in neuroscience deal
In a deal worth up to $610 million, Merck will gain a pipeline of neuroscience and rare disease programs from…
Read More » -
Bayer ends large blood thinner trial for ‘inferior efficacy’
Company shares fell by one-fifth after study monitors called for halting a planned 18,000-person trial because Bayer’s experimental drug wasn’t working…
Read More » -
Lilly plans new $2.5B manufacturing plant as obesity drug demand ramps up
Following the approval of Zepbound, Lilly is adding capacity to avert shortages and restricted access.
Read More » -
Top FDA official Woodcock to retire early next year
The 37-year veteran helmed the agency’s pandemic response, and was a key decision-maker in controversial calls on opioids, an Alzheimer's…
Read More » -
Forbion-backed biotech raises $138M to develop ALS drug
The Series A round for three-year-old startup VectorY is one of the largest private financings in Europe this year, Forbion…
Read More » -
First look at Verve study data offer base editing ‘proof of principle’
Early clinical trial results are the first for a base editing treatment and show Verve’s therapy can substantially lower cholesterol…
Read More »